Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)

Publication | Closed Access

DOI

Citations

References

2014

Year

Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, Tommaso De Pas, M. Zieliński, M.S. Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Hironao Nakayama,

Annals of Oncology

MedicineTumor ImmunityBronchial NeoplasmImmune Checkpoint InhibitorCancer TreatmentAdjuvant TherapyOncologyRadiation OncologyLung CancerRadiologyHealth Sciences